Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Cytosolic superoxide dismutase activity after photodynamic therapy, intracellular distribution of Photofrin II and hypericin, and P-glycoprotein localization in human colon adenocarcinoma.

Saczko J, Kulbacka J, Chwilkowsa A, Pola A, Lugowski M, Marcinkowska A, Malarska A, Banas T.

Folia Histochem Cytobiol. 2007;45(2):93-8.

2.

Oxidative alterations induced in vitro by the photodynamic reaction in doxorubicin-sensitive (LoVo) and -resistant (LoVoDX) colon adenocarcinoma cells.

Kulbacka J, Chwilkowska A, Bar J, Pola A, Banas T, Gamian A, Saczko J.

Exp Biol Med (Maywood). 2010 Jan;235(1):98-110. doi: 10.1258/ebm.2009.009162.

PMID:
20404024
3.

Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.

Jendzelovský R, Mikes J, Koval' J, Soucek K, Procházková J, Kello M, Sacková V, Hofmanová J, Kozubík A, Fedorocko P.

Photochem Photobiol Sci. 2009 Dec;8(12):1716-23. doi: 10.1039/b9pp00086k. Epub 2009 Oct 23.

PMID:
20024169
4.

The potential role of photodynamic therapy in the treatment of malignant melanoma--an in vitro study.

Choromańska A, Saczko J, Kulbacka J, Skolucka N, Majkowski M.

Adv Clin Exp Med. 2012 Mar-Apr;21(2):179-85.

5.

Photooxidative action in cancer and normal cells induced by the use of photofrin in photodynamic therapy.

Saczko J, Chwiłkowska A, Kulbacka J, Berdowska I, Zieliński B, Drag-Zalesińska M, Wysocka T, Lugowski M, Banaś T.

Folia Biol (Praha). 2008;54(1):24-9.

6.

Differential susceptibility of primary cultured human skin cells to hypericin PDT in an in vitro model.

Popovic A, Wiggins T, Davids LM.

J Photochem Photobiol B. 2015 Aug;149:249-56. doi: 10.1016/j.jphotobiol.2015.06.009. Epub 2015 Jun 14.

PMID:
26114219
7.

St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death.

Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM.

PLoS One. 2014 Jul 30;9(7):e103762. doi: 10.1371/journal.pone.0103762. eCollection 2014.

8.

Photoactivated hypericin increases the expression of SOD-2 and makes MCF-7 cells resistant to photodynamic therapy.

Kimáková P, Solár P, Fecková B, Sačková V, Solárová Z, Ilkovičová L, Kello M.

Biomed Pharmacother. 2017 Jan;85:749-755. doi: 10.1016/j.biopha.2016.11.093. Epub 2016 Dec 5.

PMID:
27923686
9.

Molecular determinants of photodynamic therapy for lung cancers.

Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Maehara S, Imai K, Shima K, Ohira T, Kato H, Ikeda N.

Lasers Surg Med. 2011 Sep;43(7):591-9. doi: 10.1002/lsm.21097.

PMID:
22057486
10.

Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.

Usuda J, Tsunoda Y, Ichinose S, Ishizumi T, Ohtani K, Maehara S, Ono S, Tsutsui H, Ohira T, Okunaka T, Furukawa K, Sugimoto Y, Kato H, Ikeda N.

Lung Cancer. 2010 Feb;67(2):198-204. doi: 10.1016/j.lungcan.2009.04.002. Epub 2009 May 23.

PMID:
19477032
11.

Conjunction of glutathione level, NAD(P)H/FAD redox status and hypericin content as a potential factor affecting colon cancer cell resistance to photodynamic therapy with hypericin.

Mikešová L, Mikeš J, Kovaľ J, Gyurászová K, Culka L, Vargová J, Valeková B, Fedoročko P.

Photodiagnosis Photodyn Ther. 2013 Dec;10(4):470-83. doi: 10.1016/j.pdpdt.2013.04.003. Epub 2013 May 25.

PMID:
24284100
12.

The photodynamic effect of far-red range phthalocyanines (AlPc and Pc green) supported by electropermeabilization in human gastric adenocarcinoma cells of sensitive and resistant type.

Zielichowska A, Saczko J, Garbiec A, Dubińska-Magiera M, Rossowska J, Surowiak P, Choromańska A, Daczewska M, Kulbacka J, Lage H.

Biomed Pharmacother. 2015 Feb;69:145-52. doi: 10.1016/j.biopha.2014.11.017. Epub 2014 Nov 24.

PMID:
25661351
14.

Lower sensitivity of FHC fetal colon epithelial cells to photodynamic therapy compared to HT-29 colon adenocarcinoma cells despite higher intracellular accumulation of hypericin.

Mikeš J, Hýžďalová M, Kočí L, Jendželovský R, Kovaľ J, Vaculová A, Hofmanová J, Kozubík A, Fedoročko P.

Photochem Photobiol Sci. 2011 Apr;10(4):626-32. doi: 10.1039/c0pp00359j. Epub 2011 Feb 4.

PMID:
21298151
15.

The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells.

Yang PW, Chiang TH, Hsieh CY, Huang YC, Wong LF, Hung MC, Tsai JC, Lee JM.

Lasers Med Sci. 2015 Dec;30(9):2353-61. doi: 10.1007/s10103-015-1812-8. Epub 2015 Oct 8.

PMID:
26450615
16.

In vitro study of the photocytotoxicity of bathochromically-shifted hypericin derivatives.

Roelants M, Lackner B, Waser M, Falk H, Agostinis P, Van Poppel H, de Witte PA.

Photochem Photobiol Sci. 2009 Jun;8(6):822-9. doi: 10.1039/b820817d. Epub 2009 Apr 6.

PMID:
19492110
17.

In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells.

Hajri A, Wack S, Meyer C, Smith MK, Leberquier C, Kedinger M, Aprahamian M.

Photochem Photobiol. 2002 Feb;75(2):140-8.

PMID:
11883602
18.

GJIC Enhances the phototoxicity of photofrin-mediated photodynamic treatment by the mechanisms related with ROS and Calcium pathways.

Wu D, Fan L, Xu C, Liu Z, Zhang Y, Liu L, Wang Q, Tao L.

J Biophotonics. 2015 Sep;8(9):764-74. doi: 10.1002/jbio.201400131. Epub 2015 Jan 19.

PMID:
25597481
19.

Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.

Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM.

Cancer Res. 2001 Aug 1;61(15):5824-32.

20.

ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.

Robey RW, Steadman K, Polgar O, Bates SE.

Cancer Biol Ther. 2005 Feb;4(2):187-94. Epub 2005 Feb 8.

PMID:
15684613

Supplemental Content

Support Center